To determine the dynamic secretory pattern of growth hormone (GH) in the presence of free fatty acids (FFA), we studied the effect of caprylic acid on basal and rGRF(1-29)NH 2 (GRF)-induced GH secretion in acutely dispersed and perifused rat pituitary cells. At a concentration of 3.0 mmol/L, caprylic acid inhibited both basal ( P < .05) and GRF-stimulated GH secretions ( P < .01), except when the maximal (near the EC 100) GRF concentration of 100 pmol/L was used. Lower concentrations of caprylic acid such as 0.3 and 1.0 mmol/L significantly inhibited, in a concentration-dependent manner, GH secretion induced by a 6.25-pmol/L GRF. However, at a GRF concentration of 25 pmol/L, this inhibitory effect was abolished. The time-course of GH response to GRF was similar in both control and caprylic acid-treated cells. To elucidate the mechanism(s) of action of the caprylic acid-induced blockade of GH secretion, we studied, in 3-day cultured rat pituitary cells, the effect of caprylic acid on basal and GRF-stimulated GH and 3′,5′-cyclic adenosine monophosphate (cAMP) release. We also tested its effect on the Ca 2+ ionophore, A23187-induced GH release. Caprylic acid (0.3 to 3.0 mmol/L) significantly inhibited basal GH release and GRF- or A23187-induced GH secretion. Furthermore, it decreased both basal and GRF-stimulated cAMP release ( P < .05). In addition, the effect of caprylic acid on rGRF(1-29)NH 2 affinity to GRF pituitary binding sites was determined using [ 125I-Tyr 10]hGRF(1-44)NH 2 as radioligand. This affinity was markedly diminished at 3 mmol/L caprylic acid, shifting IC 50 of competition curves performed with increasing rGRF(1-29)NH 2 concentrations (0 to 2.4 μmol/L) from 0.87 ± 0.14 nmol/L to 3.05 ± 0.65 nM ( P < .02). Finally, basal prolactin (PRL) secretion was not altered at a low caprylic acid concentration (0.3 mmol/L), while it was significantly decreased in the presence of 3.0 mmol/L caprylic acid ( P < .001). In summary, this study demonstrates that caprylic acid affects GH release by interfering with GRF receptors and altering adenylate cyclase-cAMP and calcium channel systems.